Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRLHR | P49683 | 4/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22845518 | 0.94 | PRLHR (0.35) | PRLHRTHRBHDAC6MAPTGRM5 | |
| SCHEMBL24173968 | 0.91 | PRLHR (0.36) | PRLHRMAPTPOLB | |
| SCHEMBL22845527 | 0.91 | PREP (0.37) | PRLHRMAPTGRM5KAT2BLMNA | |
| SCHEMBL22845525 | 0.90 | PRLHR (0.34) | PRLHRHDAC6MAPTPOLBTP53 | |
| SCHEMBL22845388 | 0.90 | PREP (0.35) | PRLHRHDAC6KAT2B | |
| SCHEMBL22845318 | 0.88 | PRLHR (0.33) | PRLHRGRM5 | |
| SCHEMBL22845294 | 0.85 | PRLHR (0.37) | PRLHRMAPTPOLB | |
| SCHEMBL22845373 | 0.85 | TP53 (0.35) | THRBMAPTPOLBTP53MEN1 | |
| SCHEMBL22845208 | 0.84 | PRLHR (0.35) | PRLHRHDAC6MAPTPOLBTP53 | |
| SCHEMBL22845379 | 0.84 | PREP (0.36) | PRLHRHDAC6MAPTKAT2BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885THRB 3049/4885HDAC6 12/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | PRLHR 2579/4885THRB 3049/4885HDAC6 12/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | PRLHR 2579/4885THRB 3049/4885HDAC6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.